Eli Lillys 036 Gains Overshadowed by 3075 Volume Drop as Court Dismisses Lawsuit Stock Ranks 33rd in Market Activity Amid Hims Surge

On September 3, 2025, Eli Lilly (LLY) closed with a 0.36% gain, trading with a $1.63 billion volume—a 30.75% drop from the prior day’s volume, ranking it 33rd in market activity. The stock’s performance coincided with a legal development involving its dispute with telehealth provider Willow Health, which directly impacted market sentiment.

A federal court dismissed Eli Lilly’s lawsuit against Willow Health, a competitor of Hims & Hers Health, over compounded versions of GLP-1 weight-loss drugs. The ruling, delivered by U.S. District Judge Andre Birotte Jr., concluded that Willow’s compounded formulations did not pose widespread harm and were deemed safe under federal guidelines. This decision weakened Eli Lilly’s legal argument against compounded alternatives, which have been a growing market segment. Hims & Hers Health (HIMS) surged 8.2% following the ruling, reflecting renewed confidence in the viability of compounded GLP-1 therapies.

The case is part of broader legal pressure from Eli Lilly and Novo Nordisk against telehealth companies offering lower-cost compounded drugs. Hims, which relies heavily on GLP-1 demand, faces ongoing regulatory scrutiny but has seen strong growth, with 2.4 million subscribers as of Q2 2025. The dismissal of the lawsuit temporarily eased concerns over potential litigation risks, though the company still grapples with high short interest and regulatory inquiries.

Backtesting results indicate that Eli Lilly’s stock price rose 0.36% on September 3, 2025, with a trading volume of $1.63 billion, representing a 30.75% decline from the previous day’s volume. The stock ranked 33rd in market activity for the day.